Misty mesentery is a descriptive CT term for mesenteric fat that has lost its normal near-black attenuation and looks hazy or ground glass. Its commonest cause is mesenteric panniculitis, now regarded as part of the sclerosing mesenteritis spectrum: an uncommon, idiopathic, probably autoimmune inflammatory and fibrosing disorder of mesenteric fat. Most cases are incidental, benign and need no treatment. Your job at the workstation is to apply the Coulier three-of-five CT criteria, exclude the mimics that matter (lymphoma, carcinomatosis, oedema), and flag the features that warrant biopsy or PET/CT.
Key facts for practice and radiology board exams
| What it is | Idiopathic inflammation, fat necrosis and fibrosis of the mesentery; “misty mesentery” is the CT finding, “sclerosing mesenteritis” the preferred diagnostic term |
| Prevalence on CT | 0.6% to 7.8% depending on how cases are ascertained; roughly 2% to 3% in consecutive series |
| Site | Small bowel (jejunal) mesentery in about 90%, from the mesenteric root, typically left of the midline |
| Diagnosis | At least 3 of the 5 Coulier CT signs; biopsy not required if criteria are met and there are no aggressive features (AGA 2025) |
| Symptoms | 60% or more asymptomatic; abdominal pain is the commonest symptom when present |
| Cancer link | Matched case-control studies do not support a paraneoplastic mechanism; exceptions are non-Hodgkin lymphoma and prostate cancer |
| Treatment | None if asymptomatic. If symptomatic: corticosteroid-based therapy plus tamoxifen or colchicine; no surgical cure |
Quiz
Normal density of mesenteric fat is
- -100 to -160 HU
- -40 to -60 HU
- 0 HU
- 100 HU
Terminology: misty mesentery, mesenteric panniculitis, sclerosing mesenteritis
The literature on this topic is confused because four or five names describe the same disease at different points along one spectrum. Emory and colleagues reviewed 84 archival cases at the AFIP and found that fibrosis, chronic inflammation and fat necrosis were present in every case and too intermixed to separate cleanly; they concluded these are histological variants of a single entity, for which sclerosing mesenteritis is the most appropriate term. The 2025 AGA Clinical Practice Update takes the same position, describing a continuum that includes misty mesentery and mesenteric panniculitis.
| Term | What it actually means | How to use it |
|---|---|---|
| Misty mesentery | Purely descriptive: hazy increased attenuation of mesenteric fat | A finding, not a diagnosis. Many causes |
| Mesenteric panniculitis | Inflammation and fat necrosis predominate; the usual radiological diagnosis when Coulier criteria are met | Safe to use in a CT report |
| Mesenteric lipodystrophy | Histological variant in which fat necrosis predominates | Pathology term, largely historical |
| Retractile mesenteritis | Fibrosis and retraction predominate: tethering, bowel angulation, calcification | The aggressive, symptomatic end of the spectrum |
| Sclerosing mesenteritis | Umbrella clinicopathological diagnosis covering all of the above | Preferred term (Emory 1997; AGA 2025) |
How common is mesenteric panniculitis?
Quoted prevalence varies more than tenfold, and almost all of that variation is methodological. Retrospective keyword searches of report text find only the cases someone bothered to describe; prospective review of consecutive scans finds far more.
| Study | Population | Prevalence |
|---|---|---|
| Daskalogiannaki 2000 (AJR) | 7620 consecutive abdominal CTs | 0.6% |
| Canyigit 2011 (Jpn J Radiol) | 2100 MDCT studies | 2.4% |
| Coulier 2011 (JBR-BTR) | 613 prospective consecutive MDCT | 7.8% with at least 3 of 5 signs; 3.4% when halo sign and pseudocapsule were both mandatory |
| Gogebakan 2013 (Eur J Radiol) | 13485 CTs | 0.58% |
| van Putte-Katier 2014 (Br J Radiol) | 3820 consecutive CTs | 2.5% |
| Protin-Catteau 2016 (Acta Radiol) | 3054 consecutive MDCT | 3.1% |
| Halligan 2016 (Eur Radiol, systematic review) | 14 studies, 1226 patients | 0.2% by keyword search versus 1.7% in consecutive series |
CT diagnosis: the Coulier three-of-five criteria
Coulier defined a positive CT diagnosis as the presence of at least three of five signs. This is the criterion set now endorsed by the 2025 AGA Clinical Practice Update, which states that biopsy is not required when three of five CT criteria are met and there are no features of more aggressive disease or malignancy.
| Sign | CT finding | Practical note |
|---|---|---|
| 1. Mass effect | Well-defined mesenteric “mass” that displaces adjacent bowel loops | Displacement, never invasion. Bowel wall stays normal |
| 2. Increased fat attenuation | Inhomogeneous fat, denser than adjacent retroperitoneal or mesocolonic fat | Compare against fat on the same series, not against a remembered number |
| 3. Small soft-tissue nodes | Discrete nodules embedded within the fatty mass, characteristically sub-centimetre | Nodes larger than 1 cm or confluent should raise suspicion of lymphoma |
| 4. Fat halo (fat ring) sign | Rim of preserved normal-density fat around mesenteric vessels and nodes | Suggestive but not specific: also described in mesenteric lymphoma |
| 5. Pseudocapsule | Hyperattenuating peripheral stripe bounding the process, usually under 3 mm | The single most reassuring sign of a contained, benign process |
How much does the fat density actually rise?
Normal fat measures roughly -100 to -160 HU. Measured control values are -103.9 (SD 5.8) HU for subcutaneous fat and -105 (SD 6) HU for retroperitoneal fat. In mesenteric panniculitis the abnormal fat rises to a mean of -62.8 (SD 18.6) HU in one series and -56.8 (SD 10.8) HU in another. Practical tip: place one ROI in the abnormal mesenteric fat and a second in subcutaneous or retroperitoneal fat on the same series, and quote both. The difference is what demonstrates the abnormality.
Distribution
About 90% of cases involve the small bowel mesentery, arising at the mesenteric root and characteristically extending to the left of the midline, into the left upper quadrant, along the jejunal mesentery. A 2026 3-T MRI series confirmed the same left upper quadrant predominance. Mesenteric vessels are enveloped and remain patent; they are not displaced or occluded.
Ultrasound, MRI and FDG PET/CT
| Modality | Findings | Role |
|---|---|---|
| Ultrasound | Ill-defined, predominantly hyperechoic mesenteric region with a few hypoechoic nodal elements; bowel loops displaced by a non-compressible echogenic mass | Usually an incidental or retrospective observation. Poor reproducibility, rarely diagnostic on its own |
| MRI, inflammatory type | Intermediate signal on T1, high signal on T2 and on fat-saturated fluid-sensitive sequences | Problem solving when CT is equivocal, and in young patients or repeated follow-up where dose matters |
| MRI, fibrotic (retractile) type | Low signal on both T1 and T2 with delayed progressive enhancement; no restricted diffusion on DWI | Restricted diffusion should push you towards lymphoma or carcinomatosis |
| FDG PET/CT | Absent or only low-grade uptake in uncomplicated disease. Active inflammation can produce mild uptake | Useful to exclude tumoural mesenteric involvement. Do not read any uptake as proof of malignancy |
Differential diagnosis of a misty mesentery
Misty mesentery is a finding with a long differential. Mesenteric panniculitis is only one entry, and the mimics that change management are lymphoma and peritoneal carcinomatosis.
| Cause | Discriminating features |
|---|---|
| Mesenteric oedema (cirrhosis, hypoalbuminaemia, cardiac or renal failure, bowel ischaemia) | Diffuse and symmetrical, no mass effect, no pseudocapsule. Look for ascites, bowel wall oedema and the underlying cause |
| Mesenteric lymphoma | Bulky confluent nodes over 1 cm, sandwich sign, vessels encased and displaced rather than simply enveloped, FDG avid, restricted diffusion. Note that the fat halo sign also occurs in lymphoma |
| Peritoneal carcinomatosis or mesothelioma | Nodular peritoneal thickening, omental caking, ascites, a known primary. Far more extensive peritoneal disease |
| Small bowel neuroendocrine tumour (carcinoid) | Spiculated calcified soft-tissue mesenteric mass with desmoplastic tethering of bowel; vessels encased and may be narrowed. Both calcify, but preserved perivascular fat favours panniculitis |
| Mesenteric fibromatosis (desmoid) | Solid infiltrative soft-tissue mass rather than misty fat. FAP or Gardner syndrome, prior surgery |
| Peritoneal tuberculosis | Mesenteric nodularity, necrotic lymph nodes, smooth peritoneal thickening, high-density ascites, other sites of tuberculosis |
| Mesenteric haemorrhage | Attenuation of +40 to +60 HU, T1 hyperintense, history of trauma or anticoagulation, sentinel clot |
| Contiguous inflammation (diverticulitis, appendicitis, pancreatitis, Crohn disease) | Stranding tracks to the inflamed organ; comb sign and mural hyperenhancement in Crohn disease |
| IgG4-related disease | May be histologically indistinguishable. Storiform fibrosis, obliterative phlebitis, IgG4-positive plasma cells; look for other organ involvement and serum IgG4 |
| Drug associated | Reported with BRAF/MEK inhibitors and immune checkpoint inhibitors. In melanoma patients, mesenteric panniculitis developed in 7.5% on BRAF/MEK inhibitors versus 2.9% on checkpoint inhibitors |
Red flags that should stop you calling it benign
- Lymph nodes over 1 cm, or confluent nodal masses rather than discrete small nodules. In one series the long-axis diameter of the largest node was the strongest single CT discriminator of underlying malignancy (AUC 0.879), outperforming the composite severity score
- Vessels encased and narrowed or displaced, rather than simply enveloped with preserved perivascular fat
- Bowel wall thickening, mural invasion or obstruction
- A new or enlarging discrete soft-tissue component on follow-up. Mesenteric panniculitis is remarkably stable, unchanged in about 85% of cases on follow-up CT
- Marked FDG avidity, or restricted diffusion on MRI
- Ascites, omental caking or peritoneal nodularity
Is mesenteric panniculitis a paraneoplastic sign?
This is the most argued question on the topic, and the answer has changed. Early uncontrolled series reported malignancy in half or more of patients with mesenteric panniculitis and concluded there was an association. Once matched controls were introduced, most of that association disappeared: patients who get abdominal CT are, unsurprisingly, patients who often have cancer.
| Study | Design | Finding |
|---|---|---|
| Daskalogiannaki 2000 | 49 cases, no control group | Malignancy in 34 of 49. Basis of the original “association” |
| Coulier 2011 | 613 prospective, neoplastic versus non-neoplastic groups | No significant difference overall; slight excess with prostate or bladder cancer and lymphoma. Concluded predictive value is “probably non relevant” |
| Gogebakan 2013 | First matched case-control, 77 cases versus controls | Malignancy 50.6% versus 60.2% in controls (p = 0.157). No association |
| van Putte-Katier 2014 | 94 cases, 188 matched controls, 5-year follow-up | Dissenting result: coexisting malignancy 48.9% versus 46.3%, and new malignancy over 5 years 14.6% versus 6.9% |
| Halligan 2016 | Systematic review, 14 studies, 1226 patients | Accrual bias in 64% of studies; heterogeneity prevented meta-analysis. No study can establish the link with certainty |
| Protin-Catteau 2016 | 96 cases versus 192 matched controls, 5-year follow-up | Cancer in 60.4% versus 59.4% (p = 0.86); no excess of new cancers. Concluded follow-up for cancer detection is not warranted |
| Ladron de Guevara 2026 | 1911 oncology PET/CT patients versus 1056 trauma controls | 5.2% versus 0.6% overall, but driven by non-Hodgkin lymphoma (16.1%) and prostate cancer (12.8%). Other cancers were no different from controls |
Bottom line for the report. Incidental mesenteric panniculitis meeting the Coulier criteria, with no red flags, does not justify a cancer hunt. The 2025 AGA update states that current evidence does not support a paraneoplastic mechanism. The reasonable exceptions are a lymphoma-like appearance, a patient with known or suspected prostate or urothelial cancer, and any case with the red-flag features listed above.
Clinical features
- Mostly silent. 60% or more of cases are asymptomatic and found incidentally on CT done for another reason.
- Symptoms when present: abdominal pain in about 70%, diarrhoea in 25%, weight loss in 23% in the Mayo series of 92 patients; also nausea, bloating and a palpable mass. Acute phase reactants are raised in about half.
- Attribution matters. The AGA update makes the point explicitly: the site of tenderness on examination should correspond to the lesion on imaging before the pain is blamed on it.
- Demographics: male predominance (70% male, median age 65 years in the Mayo cohort); reported across the third to ninth decades.
- Complications arise at the fibrotic, retractile end: small bowel obstruction, chylous ascites, and mesenteric venous or lymphatic obstruction.
- Associations: prior abdominal surgery or trauma, smoking, autoimmune disease, IgG4-related disease, retroperitoneal fibrosis, sclerosing cholangitis, Riedel thyroiditis and orbital pseudotumour. Recent data also link it to chronic intestinal inflammation and to BRAF/MEK inhibitor therapy.
Treatment of mesenteric panniculitis and sclerosing mesenteritis
The 2025 AGA Clinical Practice Update is the current reference point. Asymptomatic disease needs no treatment and no routine cancer workup; it is followed. Symptomatic disease is treated with anti-inflammatory medication tailored to severity and clinical response, and response typically takes months rather than weeks. There is no surgical cure.
| Regimen | Evidence |
|---|---|
| Prednisone plus tamoxifen | Long-standing first line. 60% of 20 patients improved in the 1982-2005 Mayo series; used as the initial regimen in 41.9% of a later 103-patient Mayo cohort with 55.6% improving, at a median 6.0 months |
| Prednisone alone | 57.2% improved, median 8.4 months |
| Prednisone plus colchicine | 60% improved, median 7.2 months. Statistically indistinguishable from prednisone plus tamoxifen (p = 0.85), making colchicine a reasonable first-line alternative where tamoxifen is unsuitable |
| Steroid-sparing and refractory options | Azathioprine, thalidomide, cyclophosphamide, methotrexate; biologics including rituximab, infliximab and ustekinumab are listed in the AGA update for refractory disease |
| Checkpoint inhibitor associated disease | Treated as a distinct scenario that responds readily to corticosteroids, which the AGA panel cites as support for the autoimmune nature of the condition |
| Surgery | Reserved for obstruction that fails medical therapy. Complete resection is often impossible because of mesenteric vascular involvement |
Outcome is generally good. Death from sclerosing mesenteritis is rare in modern cohorts, though the older Mayo series attributed 17% of deaths in the study period to the disease or its treatment, and the most severe cases should be referred to a centre with established expertise.
Reporting checklist
- Name the finding and state which of the five Coulier signs are present, and how many.
- Give the attenuation of the abnormal mesenteric fat and of normal subcutaneous or retroperitoneal fat from the same series.
- Report the short and long axis of the largest node. This is the number that drives the malignancy question.
- State explicitly whether vessels are enveloped with preserved perivascular fat, or encased and narrowed.
- State whether bowel is displaced or invaded, and whether there is obstruction.
- Note calcification, ascites, omental caking and peritoneal nodularity, present or absent.
- Compare with any prior imaging. Stability over years is strong evidence of benignity.
- Conclude with a diagnosis, not a description. For example: “Appearances meet 4 of 5 CT criteria for mesenteric panniculitis (sclerosing mesenteritis). No nodal enlargement, vascular encasement or peritoneal disease to suggest neoplastic mesenteric infiltration. No further imaging required if the patient is asymptomatic.”
Frequently asked questions
Classification of sclerosing mesenteritis
Etymology and synonyms
Mindelzun first used the term “misty mesentery” to describe regional increased attenuation of mesenteric fat on CT. Synonyms and near-synonyms in the literature include mesenteric lipodystrophy, mesenteric panniculitis, retractile mesenteritis, mesenteric sclerosis and inflammatory pseudotumour of the mesentery.
References
- Worthington MT, Wolf JL, Crockett SD, Pardi DS. AGA Clinical Practice Update on Sclerosing Mesenteritis: Commentary. Clin Gastroenterol Hepatol. 2025;23(6):902-907.e1. PMID: 40119869
- Coulier B. Mesenteric panniculitis. Part 2: prevalence and natural course: MDCT prospective study. JBR-BTR. 2011;94(5):241-246. PMID: 22191288
- McLaughlin PD, Filippone A, Maher MM. The “misty mesentery”: mesenteric panniculitis and its mimics. AJR Am J Roentgenol. 2013;200(2):W116-W123. PMID: 23345375
- Emory TS, Monihan JM, Carr NJ, Sobin LH. Sclerosing mesenteritis, mesenteric panniculitis and mesenteric lipodystrophy: a single entity? Am J Surg Pathol. 1997;21(4):392-398. PMID: 9130985
- Daskalogiannaki M, Voloudaki A, Prassopoulos P, et al. CT evaluation of mesenteric panniculitis: prevalence and associated diseases. AJR Am J Roentgenol. 2000;174(2):427-431. PMID: 10658720
- Akram S, Pardi DS, Schaffner JA, Smyrk TC. Sclerosing mesenteritis: clinical features, treatment, and outcome in ninety-two patients. Clin Gastroenterol Hepatol. 2007;5(5):589-596. PMID: 17478346
- Cortes P, Ghoz HM, Mzaik O, et al. Colchicine as an alternative first-line treatment of sclerosing mesenteritis: a retrospective study. Dig Dis Sci. 2022;67(6):2403-2412. PMID: 34086165
- Danford CJ, Lin SC, Wolf JL. Sclerosing mesenteritis. Am J Gastroenterol. 2019;114(6):867-873. PMID: 30829677
- Gogebakan O, Albrecht T, Osterhoff MA, Reimann A. Is mesenteric panniculitis truely a paraneoplastic phenomenon? A matched pair analysis. Eur J Radiol. 2013;82(11):1853-1859. PMID: 23906444
- Protin-Catteau L, Thiefin G, Barbe C, et al. Mesenteric panniculitis: review of consecutive abdominal MDCT examinations with a matched-pair analysis. Acta Radiol. 2016;57(12):1438-1444. PMID: 26868171
- Halligan S, Plumb A, Taylor S. Mesenteric panniculitis: systematic review of cross-sectional imaging findings and risk of subsequent malignancy. Eur Radiol. 2016;26(12):4531-4537. PMID: 27048526
- van Putte-Katier N, van Bommel EF, Elgersma OE, Hendriksz TR. Mesenteric panniculitis: prevalence, clinicoradiological presentation and 5-year follow-up. Br J Radiol. 2014;87(1044):20140451. PMID: 25271412
- Kupeli A, Cansu A, Oguz S, et al. Evaluation of mesenteric panniculitis with computed tomography: benign condition or paraneoplastic syndrome? Turk J Med Sci. 2018;48(3):569-575. PMID: 29914254
- Canyigit M, Koksal A, Akgoz A, et al. Multidetector-row computed tomography findings of sclerosing mesenteritis with associated diseases and its prevalence. Jpn J Radiol. 2011;29(7):495-502. PMID: 21882092
- Drews MA, Baumgarten A, Zensen S, et al. Adverse effects of systemic advanced melanoma therapies: do BRAF/MEK inhibitors increase the incidence of mesenteric panniculitis? Eur Radiol. 2025;35(11):7298-7306. PMID: 40310541
- Ladron de Guevara HD, Godoy LE, Zumaeta VF, et al. Frequency of mesenteric panniculitis in an oncologic population: a multicenter comparative study with a control group. Medwave. 2026;26(1):e3153. PMID: 41544202
- Buragina G, Magenta Biasina A, Carrafiello G. Clinical and radiological features of mesenteric panniculitis: a critical overview. Acta Biomed. 2019;90(4):411-422. PMID: 31910164
Case co-authored by TeamGyan Member Dr. Bhargavi Sovani. Illustrations by Dr. Bhargavi Sovani. Updated August 2026 with the 2025 AGA Clinical Practice Update on sclerosing mesenteritis.
Improve Content And Help Your Colleagues!
Found an error in the post? Please let us know using our contact page and we will update it with due credits!
If you wish to contribute radiological images for this case (or any other article on the website), you can submit them here and you will be duly credited: Submit radiology case
Thank you. Nice case.
Glad you liked it, Michael. You can check out more cases here: https://radiogyan.com/radiology-cases